--- title: Lonza expands its TheraPEAK® product portfolio with the addition of AmpliCell® Cytokine range and TheraPEAK® 293-GT® Medium description: Lonza has announced the launch of TheraPEAK® AmpliCell® Cytokines and TheraPEAK® 293-GT® Medium to expand its GMP solutions for cell and gene therapy. image: https://news.lifesciencenewswire.com/hubfs/Lonza.jpg --- [![Life Science Newswire 2](https://news.lifesciencenewswire.com/hs-fs/hubfs/Life%20Science%20Newswire%202.png?width=203&height=60&name=Life%20Science%20Newswire%202.png "Life Science Newswire 2")](https://lifesciencenewswire.com/) - [Newsroom](https://news.lifesciencenewswire.com/newsroom) - [Back to the main site](https://lifesciencenewswire.com/) ![LSNewswire-main-header-banner-v2-1](https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg "LSNewswire-main-header-banner-v2-1") # Newsroom #### Categories ![Arrow](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/sidebar.svg "Arrow") #### Subscribe![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/subscribe-rss-button.svg) ![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/close-button.svg) ### Choose a Category - [Agriculture (1)](https://news.lifesciencenewswire.com/newsroom/tag/agriculture) - [AI (1)](https://news.lifesciencenewswire.com/newsroom/tag/ai) - [Analytical Chemistry (42)](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry) - [Biomanufacturing (34)](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing) - [biopharma (21)](https://news.lifesciencenewswire.com/newsroom/tag/biopharma) - [Bioprocessing (15)](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing) - [Biotechnology (245)](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology) - [Cell Culture (9)](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture) - [Clinical Diagnostics (36)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-diagnostics) - [clinical research (6)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research) - [Clinical Research & Trials (110)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) - [Computing & Technology (62)](https://news.lifesciencenewswire.com/newsroom/tag/computing-it) - [Corporate, Finance & Investor (283)](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor) - [COVID-19 (86)](https://news.lifesciencenewswire.com/newsroom/tag/covid-19) - [Diagnostics & Hospital Laboratory (35)](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory) - [Digital Pathology (1)](https://news.lifesciencenewswire.com/newsroom/tag/digital-pathology) - [Drug Discovery & Development (148)](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development) - [Energy & Environment (15)](https://news.lifesciencenewswire.com/newsroom/tag/energy-environment) - [excipients (1)](https://news.lifesciencenewswire.com/newsroom/tag/excipients) - [Food & Beverage (8)](https://news.lifesciencenewswire.com/newsroom/tag/food-beverage) - [General Chemistry (7)](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry) - [General Laboratory (55)](https://news.lifesciencenewswire.com/newsroom/tag/general-laboratory) - [General Science (5)](https://news.lifesciencenewswire.com/newsroom/tag/general-science) - [Healthcare (133)](https://news.lifesciencenewswire.com/newsroom/tag/healthcare) - [Hospital Management (6)](https://news.lifesciencenewswire.com/newsroom/tag/hospital-management) - [Life Science (26)](https://news.lifesciencenewswire.com/newsroom/tag/life-science) - [Manufacturing (2)](https://news.lifesciencenewswire.com/newsroom/tag/manufacturing) - [Materials Science (2)](https://news.lifesciencenewswire.com/newsroom/tag/materials-science) - [Medical Devices & Technology (25)](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology) - [Microbiology & Infection Control (18)](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control) - [Microscopy & Imaging (47)](https://news.lifesciencenewswire.com/newsroom/tag/microscopy-imaging) - [Nanotech (2)](https://news.lifesciencenewswire.com/newsroom/tag/nanotech) - [Omics & Genetics (86)](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics) - [Pathology (5)](https://news.lifesciencenewswire.com/newsroom/tag/pathology) - [Pharma (115)](https://news.lifesciencenewswire.com/newsroom/tag/pharma) - [Pharmacy (4)](https://news.lifesciencenewswire.com/newsroom/tag/pharmacy) - [Research (47)](https://news.lifesciencenewswire.com/newsroom/tag/research) - [Veterinary (5)](https://news.lifesciencenewswire.com/newsroom/tag/veterinary) - [Water (8)](https://news.lifesciencenewswire.com/newsroom/tag/water) See all ### Subscribe to Email Updates - ##### SHARE - - - # [Lonza expands its TheraPEAK® product portfolio with the addition of AmpliCell® Cytokine range and TheraPEAK® 293-GT® Medium](https://news.lifesciencenewswire.com/newsroom/lonza-expands-its-therapeak-product-portfolio-with-the-addition-of-amplicell-cytokine-range-and-therapeak-293-gt-medium) October 6, 2025 - AmpliCell® Cytokines enable cell expansion optimization, batch-to-batch consistency and easy transition from research to manufacturing - TheraPEAK® 293-GT® Medium System aims to help accelerate development timelines and improve consistency from research through to GMP gene therapy production [![TheraPEAK 293-GT media system for suspension HEK203 cell lines](https://news.lifesciencenewswire.com/hs-fs/hubfs/Lonza.jpg?width=312&height=312&name=Lonza.jpg)](https://drive.google.com/file/d/1a-v6tAyn7dEJLZAHtgR3YwiKlJ0aj73C/view?usp=drive_link)Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), today announced the launch of TheraPEAK® AmpliCell® Cytokines and TheraPEAK® 293-GT® Medium to expand its GMP solutions for cell and gene therapy. Cytokines represent a critical component in cell therapy manufacturing, supporting the expansion and maintenance of living cells. TheraPEAK® AmpliCell® Cytokines enable the reliable expansion, activation, and differentiation of immune cells. Produced in a mammalian expression system and engineered for high biological activity, these cytokines feature proper folding and glycosylation, delivering native-like structure and function that bacterial systems cannot match. This ensures superior biological relevance, batch-to-batch consistency, and greater predictability in sensitive and translational applications, both in research and GMP set-ups. [![TheraPEAK AmpliCell Recombinant Interleukin Cytokines](https://news.lifesciencenewswire.com/hs-fs/hubfs/TheraPEAK%20AmpliCell%20Recombinant%20Interleukin%20Cytokines.jpg?width=318&height=238&name=TheraPEAK%20AmpliCell%20Recombinant%20Interleukin%20Cytokines.jpg)](https://drive.google.com/file/d/1gxxE1Rt96vi0Vuvq1LismEQ37q_eJVOh/view?usp=drive_link) TheraPEAK® 293-GT® Medium is a chemically defined, animal–origin–free system optimized for adeno-associated virus (AAV) production in suspension HEK293 cells, providing a reliable, scalable option for advancing gene therapy programs. Unlike off-the-shelf viral production kits that may lack flexibility, the 293-GT® System (growth medium plus supplement) is a drop-in-ready solution engineered to integrate seamlessly with existing workflows. The media is compatible with commercially available transfection reagents and AAV enhancers, delivers strong AAV titers, and supports high full-to-empty capsid ratios.   TheraPEAK® Products have been used in FDA-approved therapies and more than 130 clinical trials across the globe. The newly-added solutions provide researchers and manufacturers with high-performance, scalable, and regulatory-ready solutions that streamline cell and gene therapy workflows from discovery through clinical development. Mike Goetter, Head of Bioscience, Specialized Modalities, Lonza, said: “The introduction of AmpliCell® Cytokines and the 293-GT® Medium to our TheraPEAK® Range greatly enhances our offering for cell and gene therapy customers, providing them with reliable solutions to support their drug development efforts.” Additional Information To learn more about Lonza’s TheraPEAK® products, visit: [https://bioscience.lonza.com/lonza\_bs/GB/en/consistency-you-can-count-on-therapeak-amplicell-cytokines](https://bioscience.lonza.com/lonza_bs/GB/en/consistency-you-can-count-on-therapeak-amplicell-cytokines) Categories: [Biomanufacturing](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing), [Clinical Research & Trials](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) ##### Browse more news ## Recent releases #### [ARScience Biotherapeutics Initiates Technology Transfer for Commercial Manufacturing of Low Dose Int...](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-initiates-technology-transfer-for-commercial-manufacturing-of-low-dose-interleukin-2) July 22, 2026 Milestone marks the transition of Low Dose IL-2 from clinical development to a scalable, regulatory-ready commercial manufacturing process Strategic s... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-initiates-technology-transfer-for-commercial-manufacturing-of-low-dose-interleukin-2) #### [Trajan expands US availability of Harpera™ Microbiopsy Punch for clinical skin sampling](https://news.lifesciencenewswire.com/newsroom/trajan-expands-us-availability-of-harpera-microbiopsy-punch-for-clinical-skin-sampling) July 20, 2026 New registration expands access to minimally invasive skin microbiopsy for clinical, research, and wellness applications. Trajan today announced the H... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/trajan-expands-us-availability-of-harpera-microbiopsy-punch-for-clinical-skin-sampling) #### [CellCarta Launches Digital Pathology and AI Consortium to Accelerate Platform-Agnostic Biomarker Inn...](https://news.lifesciencenewswire.com/newsroom/cellcarta-launches-digital-pathology-and-ai-consortium-to-accelerate-platform-agnostic-biomarker-innovation-across-drug-development) July 15, 2026 Consortium initially brings together Lunit, Mindpeak, Imagene AI, Dipath AI, Nucleai, Tivenix and Indica Labs to give biopharma sponsors a single CRO-... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/cellcarta-launches-digital-pathology-and-ai-consortium-to-accelerate-platform-agnostic-biomarker-innovation-across-drug-development) ![LS-Newswire-reverse](https://news.lifesciencenewswire.com/hs-fs/hubfs/raw_assets/public/LifeScienceNewswire_June2020/images/LS-Newswire-reverse.png?width=150&name=LS-Newswire-reverse.png "LS-Newswire-reverse") Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225  #### Useful information - [Cookie and privacy policy](https://lifesciencenewswire.com/cookie-privacy-policy/) - [Website terms and conditions](https://lifesciencenewswire.com/terms-and-conditions) - [Promotion terms and conditions](https://lifesciencenewswire.com/promotion_terms/)